The China Securities Regulatory Commission has approved the registration of Tongze Kangwei's IPO on the Growth Enterprise Board.
On July 31, the China Securities Regulatory Commission issued the "Reply on Approving the Registration of the Initial Public Offering of Shares by Guangzhou Tongze Kangwei Technology Co., Ltd."
On July 31, the China Securities Regulatory Commission announced its approval of the initial public offering registration of Guangzhou Tongze Kangwei Technology Co., Ltd. It is reported that Tongze Kangwei plans to be listed on the ChiNext board of the Shenzhen Stock Exchange, with China Securities Co., Ltd. as the sponsor, aiming to raise 1.38111 billion yuan.
According to the prospectus, Tongze Kangwei primarily engages in the design, development, production, and sales of self-developed series of broadband terminal equipment, mainly providing product services directly to global telecommunications operators, and actively expanding applications for vertical industry customers.
Related Articles

HSBC HOLDINGS (00005) spent HKD 49.5541 million to repurchase 304,800 shares on August 21.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874): The injection of dextroamphetamine sulfate (1ml:2mg) has passed the consistency evaluation of generic drugs.

LONGCHEER (09611) invested 4.5007 million yuan on August 24 to repurchase 122,200 A-shares.
HSBC HOLDINGS (00005) spent HKD 49.5541 million to repurchase 304,800 shares on August 21.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874): The injection of dextroamphetamine sulfate (1ml:2mg) has passed the consistency evaluation of generic drugs.

LONGCHEER (09611) invested 4.5007 million yuan on August 24 to repurchase 122,200 A-shares.

RECOMMEND





